

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

INNOVATIVE MEDICINES

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

TRANSFORMATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS BIOMANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

AMGEN FACT SHEET | 2022

Amgen Quick Facts:

Headquarters

Thousand Oaks, California

Staff

Approximately 24,000 worldwide

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Robert A. Bradway

2021 Financial Highlights

Total revenue: USD 26.0 billion Product sales: USD 24.3 billion R&D expense: USD 4.8 billion

VALUES

- Be Science-Based
- Compete Intensely and Win
- Create Value for Patients, Staff and Stockholders
- Be Ethical
- Trust and Respect Each Other
- Ensure Quality
- Work in Teams
- Collaborate, Communicate and Be Accountable



About Amgen Australia

Established in 1991 and headquartered in Sydney, Amgen Australia works to further the company's global efforts to transform the promise of science and biotechnology into therapies that restore health and save lives. Hundreds of thousands of Australians use one of Amgen's 18 products and thousands more have been enrolled in clinical studies that have helped deliver the next generation of innovative treatments. Amgen Australia is proud to support these patients and to contribute to the development of new therapies in partnership with Australia's leading healthcare, academic, research, government, and patient organisations.

LOCAL RESEARCH AND DEVELOPMENT

Amgen maintains an extensive clinical trial program and invests significantly in research and development. Amgen's history of clinical trial activity in Australia dates back 35 years and our reputation for quality and safety continues to make us one of the most trusted destinations in the world for Amgen research. In 2021, this included over 600 Australian patients, participating in more than 50 clinical trials and 20 investigator-sponsored studies at leading Australian hospitals.

COMMUNITY SUPPORT

Making a positive difference in the world is at the heart of what we do at Amgen – and it goes beyond making vital medicines. Each year, Amgen and our staff members dedicate significant resources towards building a better tomorrow. This includes:

The Amgen Foundation – advancing excellence in science education to inspire the next generation of innovators through signature programs including The Amgen Biotech Experience and Amgen Scholars.

The Amgen Biotech Experience, launched in Australia in 2017 through a partnership with The University of Sydney, provides professional development for teachers as well as teaching materials and research-grade equipment to classrooms to help educate high school students about the concepts and techniques scientists use to produce medicines.

Amgen Scholars, a partnership with The University of Melbourne which launched in 2018, provides hands-on research experience in leading laboratories to undergraduate science students across Australia, New Zealand an Oceania. For further information on Amgen's commitment to STEM education, visit our website.

Patient organisation support – proudly helping leading Health Consumer Organisations such as Rare Cancers Australia, Healthy Bones Australia, Lung Foundation Australia, National Heart Foundation, Myeloma Australia, and Prostate Cancer Foundation of Australia in their efforts to provide information, support and resources that improve prevention, diagnosis, treatment, and survival.

Donations – enabling the work of others through donations, particularly in the areas of clinical research and ongoing medical education.

Staff volunteering – providing paid charity leave so staff can donate man-hours to community groups, support local charities and participate in our Annual Week of Service. Each year, hundreds of hours of assistance are provided to people and organisations in need.

Environment – designing practices to measure and reduce our environmental impact, particularly regarding product packaging.

REWARDING CAREERS

Amgen Australia offers rewarding career opportunities. Our dedicated and accomplished team bring curiosity, energy, and optimism to prevail over ever-evolving challenges. Amgen is an Equal Employment Opportunity / Affirmative Action employer committed to building an environment of diversity, inclusion and belonging that fosters innovation, strengthens our global workforce, and drives our ability to serve patients. To stay up to date on news and opportunities, visit our website and join our Talent Network.



Australian Office

Amgen Australia Pty Ltd Level 11, 10 Carrington Street Sydney NSW 2000 T: +61 2 9870 1333 W: www.amgen.com.au ABN 31 051 057 428

Medical Information

T: 1800 803 638 (toll free)

Managing Director

Gabi Mittas

2021 Revenue

AUD 416 million

Staff

216 permanent employees

PRODUCTS

AMGEVITA® (adalimumab)

Aranesp® (darbepoetin alfa)

BLINCYTO® (blinatumomab)

EVENITY® (romosozumab-aqqq)

KANJINTI® (trastuzumab-anns)

KYPROLIS® (carfilzomib)

LUMAKRAS® (sotorasib)

MVASI® (bevacizumab-awwb)

Neulasta® / RISTEMPA® / TEZMOTA® (pegfilgrastim)

NEUPOGEN® (filgrastim)

Nplate® (romiplostim)

Otezla® (apremilast)

Prolia® (denosumab)

Repatha® (evolocumab)

Vectibix® (panitumumab)

XGEVA® (denosumab)

For further information about our pipeline and therapies, visit www.amgen.com.au

Affiliations

Amgen is a proud member of:

- Medicines Australia
- AusBiotech
- American Chamber of Commerce in Australia (AmCham)
- Australian Packaging Covenant Organisation

